US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Renaissance Technologies Holdings

1,912.72

+10.760.57%

Number of Gainers:68

Number of Losers:27

Number of Flat:1

PE:- -

High:1,918.65

Open:1,901.96

Low:1,875.77

Close:1,901.96

Loading ...

Cogent Biosciences Announces Participation in the Leerink Healthcare Conference

BUZZ-Deutsche Bank initiates coverage on some US railroad operators

Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer

MT Newswires Live

Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK

MT Newswires Live

VeriSign's (NASDAQ:VRSN) investors will be pleased with their respectable 45% return over the last five years

Simply Wall St.

CSX Corp : Deutsche Bank Initiates Coverage With Hold Rating; Target Price $34

THOMSON REUTERS

Johnson & Johnson Unit's Lazertinib With Amivantamab Approved in UK for Non-Small Cell Lung Cancer

MT Newswires Live

Positive Outlook for Jazz Pharmaceuticals: Buy Rating Backed by Strong Growth Prospects and Strategic Focus

Balanced Outlook for Kroger: Opportunities Amidst Leadership Changes and Market Volatility

Six questioned by police over protest in NUS on Israel-Hamas war

Analysts Offer Insights on Financial Companies: Marketaxess Holdings (MKTX) and JPMorgan Chase & Co. (JPM)

Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer

Daiwa Adjusts Price Target on Target to $120 From $130, Maintains Neutral Rating

MT Newswires Live

BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab)

IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4532/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4532"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","market":"US","secType":"PLATE","nameCN":"Renaissance Technologies Holdings","latestPrice":1912.7213,"timestamp":1741381199999,"preClose":1901.9585,"halted":0,"volume":1124904543,"delay":0,"changeRate":0.005659,"change":10.762817,"pbRate":8.603584,"amount":135119673650.74295,"amplitude":0.022546,"prevYearClose":2026.1482,"fiveDayClose":1965.7411,"twentyDayClose":2044.8126,"turnoverRate":0.008743,"marketCap":21363470568128,"floatMarketCap":19968293404480,"peRate":31.475371},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4532\",,,,,undefined,":{"symbol":"BK4532","high":1918.6505,"amplitude":0.022546,"preClose":1901.9585,"low":1875.7682,"pbRate":"8.603584","latestPrice":1912.7213,"volume":1124904543,"delay":0,"open":1901.9614,"prevYearClose":2026.1482,"prevWeekClose":1965.7411,"prevMonthClose":1965.7411,"prevQuarterClose":2026.1482,"fiveDayClose":1965.7411,"twentyDayClose":2044.8126,"sixtyDayClose":2084.0764,"secType":"PLATE","market":"US","turnoverRate":0.008743,"peRate":31.475371,"marketCap":21363470568128,"floatMarketCap":19968293404480,"timestamp":1741381199999,"nameCN":"Renaissance Technologies Holdings"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4532\",,,,undefined,":{"bkCode":"BK4532","up":68,"down":27,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4532\",pageSize:16,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517480528","title":"Cogent Biosciences Announces Participation in the Leerink Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480528","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480528?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:00","pubTimestamp":1741352400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass. and BOULDER, Colo., March  07, 2025  (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.(Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/07/3038914/0/en/Cogent-Biosciences-Announces-Participation-in-the-Leerink-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","BK4532","LU1670628061.USD","BK4089","BK4137","CCOI","LU1670627923.USD"],"gpt_icon":0},{"id":"2517871024","title":"BUZZ-Deutsche Bank initiates coverage on some US railroad operators","url":"https://stock-news.laohu8.com/highlight/detail?id=2517871024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517871024?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:58","pubTimestamp":1741352284,"startTime":"0","endTime":"0","summary":"BUZZ-Deutsche Bank initiates coverage on some US railroad operators** Deutsche Bank initiates coverage on some U.S. railroad operators, including Norfolk Southern NSC.N and Union Pacific UNP.N, with \"buy\" rating ** Says NSC's margin improvement trend will continue into 2025; has PT of $293, implying a 23% upside to stock's last close** Sets PT of $295 on UNP, representing a 20% upside to stock's last close** Initiates coverage on CSX CSX.O with \"hold\" and PT of $34, a 9% upside to stock's last close** \"CSX faces several cost challenges and investment requirements in 2025, which, we believe, will restrict its ability to achieve attractive EPS growth\" - brokerage ** S&P 500 Rail Transportation .SPLRCRAIL sub-index up 3.4% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PQ12A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4520","LU0302445910.USD","LU0661504455.SGD","IE00BMG7P694.USD","IE00BMG7P702.HKD","LU0820561909.HKD","LU0738911758.USD","LU1303367103.USD","LU2756315664.SGD","BK4585","LU0124384867.USD","UNP","IE00B29SXK94.USD","IE00BLSP4239.USD","LU1003077747.HKD","GB00BDT5M118.USD","LU2244417387.USD","IE00B29SXL02.USD","LU2346227817.USD","IE00BD4GTW91.USD","NSC","LU0312595415.SGD","LU1978683503.SGD","BK4581","LU0354030438.USD","BK4566","LU0048573561.USD","CSX","IE00BMG7P587.USD","BK4588","IE00BSNM7G36.USD","BK4532","LU0553294199.USD","BK4534","LU2756315318.SGD","LU0187121727.USD","LU1861214812.USD","LU0689472784.USD","IE00B775SV38.USD","LU0354030511.USD","LU0742534661.SGD","LU0820562030.AUD","LU1861219969.SGD","LU2098885051.SGD","LU1551013342.USD","BK4016","LU2275660780.HKD","LU0251131958.USD","IE00BLSP4452.SGD","LU0943347566.SGD"],"gpt_icon":0},{"id":"2517487820","title":"Bristol-Myers Squibb Says Opdivo With Yervoy Approved in EU to Treat Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517487820","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517487820?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:53","pubTimestamp":1741351995,"startTime":"0","endTime":"0","summary":"Bristol-Myers Squibb  said Friday the European Commission has approved Opdivo plus Yervoy as the first-line treatment for adults with unresectable or advanced hepatocellular carcinoma, the most common type of liver cancer.The company said the approval applies across all 27 EU member states, along with Iceland, Liechtenstein, and Norway.Bristol-Myers Squibb said the approval is based on a phase 3 clinical study that showed dual immunotherapy treatment with Opdivo, or nivolumab, and Yervoy, or ipilimumab, resulted in median overall survival of 23.7 months and overall response rate of 36.1%.In the US, the company said its supplemental Biologics License Application for Opdivo plus Yervoy in unresectable hepatocellular carcinoma has a target action date of April 21.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0096364046.USD","BK4007","BK4534","LU2125154778.USD","LU0306806265.USD","BK4585","IE00BFTCPJ56.SGD","LU1585245621.USD","LU1670710588.SGD","LU1989771016.USD","LU0321505439.SGD","LU1074936037.SGD","LU1291159041.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1670711040.USD","LU2133065610.SGD","LU1868837300.USD","BK4581","LU1718418525.SGD","LU1868836914.USD","LU1261432733.SGD","LU1868836591.USD","LU1868836757.USD","LU2360032135.SGD","BK4156","IE00B2B36J28.USD","LU1093756325.SGD","LU1571399168.USD","IE00BFXG1179.USD","LU2242646821.SGD","LU1093756168.USD","BK4532","LU2125154935.USD","LU1670711123.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","LU0225771236.USD","LU0456855351.SGD","BK4588","LU1868837136.USD","LU0321505868.SGD","LU0225284248.USD","LU0306807586.USD","IE00BSNM7G36.USD","BMY","LU0061475181.USD","LU0985481810.HKD","BK4559"],"gpt_icon":0},{"id":"2517448228","title":"Vertex Pharmaceuticals' Triple Combination Cystic Fibrosis Therapy Alyftrek Receives Approval in UK","url":"https://stock-news.laohu8.com/highlight/detail?id=2517448228","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517448228?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:46","pubTimestamp":1741351613,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals' (VRTX) triple combination medicine deutivacaftor, tezacaftor,vanzacaftor was approved by the UK's Medicines and Healthcare products Regulatory Agency for treating cystic fibros","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BZ9MQY76.HKD","IE00B19Z9Z06.USD","LU0079474960.USD","VRTX","LU0058720904.USD","LU0320765992.SGD","LU0061475181.USD","LU2236285917.USD","BK4533","IE00B19Z3B42.SGD","LU0889565916.HKD","LU2456880835.USD","LU1585245621.USD","VERX","IE00B894F039.SGD","IE0009355771.USD","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","LU2362541513.USD","LU1093756325.SGD","BK4588","LU0417517546.SGD","IE00B2B36J28.USD","LU2324357040.USD","LU2462157665.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU1035775433.USD","LU2362540622.SGD","LU2362541273.HKD","BK4532","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU1069344957.HKD","LU1093756168.USD","BK4567","IE0002270589.USD","BK4585","LU0823416689.USD","LU2237438978.USD","LU2417539215.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","LU1430594728.SGD","LU0234570918.USD"],"gpt_icon":0},{"id":"2517480385","title":"VeriSign's (NASDAQ:VRSN) investors will be pleased with their respectable 45% return over the last five years","url":"https://stock-news.laohu8.com/highlight/detail?id=2517480385","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517480385?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:37","pubTimestamp":1741351051,"startTime":"0","endTime":"0","summary":"When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But VeriSign, Inc.  has fallen short of that second goal, with a share price rise of 45% over five years, which is below the market return. Some buyers are laughing, though, with an increase of 25% in the last year.So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share  with the share price.Over half a decade, VeriSign managed to grow its earnings per share at 10.0% a year. This EPS growth is higher than the 8% average annual increase in the share price. So ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verisigns-nasdaq-vrsn-investors-pleased-123731670.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NDAQ","TSYW.SI","TQQQ","PSQ","LU0823417737.USD","QLD","LU0950375773.USD","IE00BGHQF748.EUR","LU1043141396.HKD","NVIW.SI","LU2506952170.USD","LU2506951958.HKD","IE00B3QW5Z07.USD","BK4112","USAW.SI","LU0234570918.USD","USJW.SI","LU2210150020.SGD","LU1043141123.HKD","BK4588","BK4116","LU0426417589.USD","LU2210149790.SGD","LU0348723411.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","BK4559","VRSN","LU1121112475.USD","LU2095319765.USD","LU2506952097.USD","LU2506951875.HKD","BK4532","LU0823417653.USD","LU1571399168.USD","LU0994945656.USD","MNQmain","SQQQ","QID",".IXIC","NQmain","LU0426412945.USD"],"gpt_icon":1},{"id":"2517185484","title":"CSX Corp : Deutsche Bank Initiates Coverage With Hold Rating; Target Price $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2517185484","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517185484?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:28","pubTimestamp":1741350515,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BD4GTW91.USD","BK4520","IE00B29SXK94.USD","BK4566","IE00B29SXL02.USD","IE00B3S45H60.SGD","IE00BD4GTT62.SGD","BK4532","BK4585","IE00BD4GTV84.USD","IE00B775SV38.USD","IE00BSNM7G36.USD","LU2346227817.USD","BK4588","CSX","LU1074936037.SGD","BK4016"],"gpt_icon":0},{"id":"2517849094","title":"Johnson & Johnson Unit's Lazertinib With Amivantamab Approved in UK for Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517849094","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517849094?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:25","pubTimestamp":1741350310,"startTime":"0","endTime":"0","summary":"Johnson & Johnson's (JNJ) Janssen-Cilag subsidiary has received marketing authorization in the UK for lazertinib combined with amivantamab to treat adults with a type of non-small cell lung cancer, th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","LU2089984988.USD","BK4504","IE0009355771.USD","LU1935042991.SGD","LU2129689605.HKD","IE00B2B36J28.USD","LU0122379950.USD","LU1061106388.HKD","BK4532","JNJ","SG9999001440.SGD","LU0345770993.USD","LU1221951129.SGD","LU1585245621.USD","LU0640476718.USD","BK4581","LU2430703095.HKD","LU1066053197.SGD","LU2133065610.SGD","LU0345770308.USD","LU1267930813.SGD","IE00BFTCPJ56.SGD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1430594728.SGD","BK4588","IE00B7SZLL34.SGD","LU1280957306.USD","BK4559","LU1196500208.SGD","SG9999002224.SGD","BK4534","LU1244550221.USD","LU1261432733.SGD","LU1032466523.USD","LU1506573853.SGD","LU2602419157.SGD","LU1778281490.HKD","LU0234572021.USD","LU0320765646.SGD","LU0345769631.USD","LU1674673428.USD","IE00BVYPNW00.USD","LU1066051225.USD","LU1032955483.USD","LU1894683348.USD","BK4533","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2517845354","title":"Positive Outlook for Jazz Pharmaceuticals: Buy Rating Backed by Strong Growth Prospects and Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2517845354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517845354?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:17","pubTimestamp":1741349872,"startTime":"0","endTime":"0","summary":"Sean Laaman, an analyst from Morgan Stanley, has initiated a new Buy rating on Jazz Pharmaceuticals (JAZZ). Sean Laaman has given his Buy rating du...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-jazz-pharmaceuticals-buy-rating-backed-by-strong-growth-prospects-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-jazz-pharmaceuticals-buy-rating-backed-by-strong-growth-prospects-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023251221.USD","IE00BN0W2T93.GBP","LU1989772923.USD","LU2133065610.SGD","LU0320765646.SGD","LU0823416689.USD","LU0106261372.USD","IE00BN0W2V16.EUR","BK4588","LU1989772840.SGD","LU0795875169.SGD","IE00BZ1G4Q59.USD","BK4533","LU2271345857.HKD","LU0225283273.USD","LU1732799900.SGD","LU0971096721.USD","LU0320765992.SGD","BK4007","BK4585","LU0267386448.USD","IE00BN0W2W23.USD","BK4532","LU0006306889.USD","JAZZ","BK4534","LU0912757837.SGD","LU1074936037.SGD","LU2028103732.USD","LU2089284900.SGD","LU2111349929.HKD","BK4127","LU1363072403.SGD","BK4516","LU1720051017.SGD","LU2347655156.SGD","LU0158827781.USD","LU0889565916.HKD","LU0795875086.SGD","LU1162221912.USD","LU1668664300.SGD","LU1732800096.USD","LU2089283258.USD","LU0314104364.USD","BK4504","LU0158827948.USD","LU0106831901.USD","BK4581","LU0109394709.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2517548459","title":"Balanced Outlook for Kroger: Opportunities Amidst Leadership Changes and Market Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2517548459","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517548459?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:17","pubTimestamp":1741349827,"startTime":"0","endTime":"0","summary":"Kroger Company (KR – Research Report), the Consumer Defensive sector company, was revisited by a Wall Street analyst today. Analyst Simeon Gutman f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-outlook-for-kroger-opportunities-amidst-leadership-changes-and-market-volatility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-outlook-for-kroger-opportunities-amidst-leadership-changes-and-market-volatility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4113","BK4504","LU0312595415.SGD","LU0302445910.USD","LU0345770308.USD","BK4533","LU1201861249.SGD","LU0345770993.USD","LU0477156953.USD","BK4559","LU0648001328.SGD","BK4585","KR","LU0980610538.SGD","LU0130102774.USD","BK4532","LU0130517989.USD","BK4588","LU2275660780.HKD"],"gpt_icon":0},{"id":"2517459438","title":"Six questioned by police over protest in NUS on Israel-Hamas war","url":"https://stock-news.laohu8.com/highlight/detail?id=2517459438","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517459438?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:15","pubTimestamp":1741349704,"startTime":"0","endTime":"0","summary":"The police also confirmed communication devices and clothing linked to the incident were seized as part of investigations.","market":"nz","thumbnail":"https://dam.mediacorp.sg/image/upload/s--INH00ujg--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/01/16/screenshot_2025-01-16_172931.png?itok=QvN3LB00","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--INH00ujg--/c_fill,g_auto,h_468,w_830/f_auto,q_auto/v1/mediacorp/cna/image/2025/01/16/screenshot_2025-01-16_172931.png?itok=QvN3LB00"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/singapore/6-people-questioned-police-nus-protest-israel-hamas-conflict-phones-clothing-seized-no-permit-4985406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["BK4585","BK4183","BK4532","NUS"],"gpt_icon":0},{"id":"2517348451","title":"Analysts Offer Insights on Financial Companies: Marketaxess Holdings (MKTX) and JPMorgan Chase & Co. (JPM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517348451","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517348451?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:13","pubTimestamp":1741349581,"startTime":"0","endTime":"0","summary":"Companies in the Financial sector have received a lot of coverage today as analysts weigh in on Marketaxess Holdings (MKTX – Research Report) and J...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-financial-companies-marketaxess-holdings-mktx-and-jpmorgan-chase-co-jpm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-financial-companies-marketaxess-holdings-mktx-and-jpmorgan-chase-co-jpm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0943347566.SGD","LU2552382058.USD","IE00BLSP4239.USD","LU1084165304.USD","JPMLL","LU1670628061.USD","LU0048584097.USD","IE00BZ1G4Q59.USD","LU0211327993.USD","LU2430703251.USD","IE00BLSP4452.SGD","IE00BKDWB100.SGD","LU0882574139.USD","LU1670627923.USD","LU1496350502.SGD","LU0820562030.AUD","BK4585","IE0034235188.USD","LU1261432733.SGD","LU0267386448.USD","LU0256863811.USD","IE0034235303.USD","LU2213496289.HKD","BK4532","LU0320765489.SGD","IE00BYXW3230.USD","LU2237443549.SGD","MKTX","LU0203347892.USD","LU0070302665.USD","BK4207","LU0215105999.USD","LU0868494708.USD","LU0683600562.USD","BK4516","LU2357305700.SGD","IE00BBT3K403.USD","BK4550","LU1720051017.SGD","LU1974910355.USD","LU2756315664.SGD","IE00BHPRN162.USD","IE00BJLML261.HKD","LU1162221912.USD","LU2023250843.SGD","LU1629891620.HKD","LU0942090050.USD","BK4504","LU0106831901.USD","LU2505996509.AUD"],"gpt_icon":0},{"id":"2517828944","title":"Bristol Myers Gets Expanded Europe OK of Opdivo/Yervoy Combo in Liver Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517828944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517828944?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:12","pubTimestamp":1741349520,"startTime":"0","endTime":"0","summary":"Bristol Myers Squibb has won the European Commission's expanded approval of its Opdivo plus Yervoy cancer-drug combination for early use in certain patients with liver cancer.Bristol Myers on Friday said the approval covers the combination for the first-line treatment of adults with unresectable or advanced hepatocellular carcinoma.Liver cancer is the third most frequent cause of cancer death worldwide, and hepatocellular carcinoma is the most common type of liver cancer, accounting for 90% of global cases, the Princeton, N.J., biopharmaceutical company said.The Opdivo/Yervoy combination is already approved in several cancer indications worldwide. The U.S. Food and Drug Administration is reviewing the combination as a potential first-line treatment option for adults with unresectable hepatocellular carcinoma, with a target action date of April 21.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0061475181.USD","LU1093756325.SGD","LU1323610961.USD","LU1868836914.USD","LU2360032135.SGD","LU1093756168.USD","IE00BFXG1179.USD","LU1868837300.USD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU0882574055.USD","LU1670710661.SGD","LU1670711040.USD","LU0321505439.SGD","BK4126","BK4585","LU1291159041.SGD","LU2125154778.USD","LU0114720955.EUR","LU1585245621.USD","LU0985481810.HKD","MYE","IE00BSNM7G36.USD","BK4559","LU0306807586.USD","LU1868836591.USD","LU1032466523.USD","LU2125154935.USD","LU1571399168.USD","BMY","BK4581","BK4534","LU1670711123.USD","LU1868836757.USD","BK4007","LU1718418525.SGD","LU1989771016.USD","LU1261432733.SGD","LU1074936037.SGD","LU2133065610.SGD","IE00B2B36J28.USD","LU2242652126.USD","IE00BJT1NW94.SGD","LU0321505868.SGD","LU0868494617.USD","LU1430594728.SGD","LU0456855351.SGD","LU0225771236.USD","LU1670710588.SGD","BK4532"],"gpt_icon":0},{"id":"2517629481","title":"Daiwa Adjusts Price Target on Target to $120 From $130, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2517629481","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517629481?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:05","pubTimestamp":1741349111,"startTime":"0","endTime":"0","summary":"Target (TGT) has an average rating of overweight and mean price target of $135.04, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4114","LU2237443622.USD","LU0310799852.SGD","BK4155","LU1267930227.SGD","LU1244550577.SGD","BK4504","BK4585","BK4597","LU0128525689.USD","LU2237443549.SGD","LU2237443382.USD","LU0823411888.USD","LU1244550494.USD","BK4588","BK4532","LU0211327993.USD","LU2237443978.SGD","LU1267930490.SGD","LU0310800965.SGD","LU0211328371.USD","LU0052756011.USD","BK4596","LU1244550221.USD","BK4533"],"gpt_icon":0},{"id":"2517648909","title":"BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo® (Nivolumab) Plus Yervoy® (Ipilimumab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517648909","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517648909?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348832,"startTime":"0","endTime":"0","summary":"BRIEF-Bristol Myers Squibb Receives European Commission Approval For Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) March 7 (Reuters) - Bristol-Myers Squibb Co BMY.N:BRISTOL MYERS SQUIBB RECEIVES EUROPEA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nFWN3PQ0SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1032466523.USD","LU1093756168.USD","LU0456855351.SGD","LU1718418525.SGD","BK4559","LU0868494617.USD","IE00BJJMRZ35.SGD","LU1868836914.USD","LU0321505439.SGD","LU2125154935.USD","LU1261432733.SGD","IE00BFTCPJ56.SGD","LU1868837300.USD","LU0061475181.USD","BMY","IE0002141913.USD","LU0114720955.EUR","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU2242646821.SGD","BK4585","LU0225771236.USD","BK4534","LU0096364046.USD","LU1074936037.SGD","LU2125154778.USD","BK4532","LU1323610961.USD","LU2133065610.SGD","LU0237698245.USD","LU0985481810.HKD","LU1670711040.USD","IE0009355771.USD","LU0882574055.USD","LU1430594728.SGD","LU1868837136.USD","LU1093756325.SGD","LU1868836757.USD","LU1670710588.SGD","LU0306807586.USD","LU1571399168.USD","LU2242652126.USD","LU1670711123.USD","LU1868836591.USD","LU0306806265.USD","BK4588","BK4007","IE00BSNM7G36.USD","LU1585245621.USD","LU0321505868.SGD"],"gpt_icon":0},{"id":"2517482934","title":"IMFINZI® (durvalumab)-based regimen demonstrated statistically significant and clinically meaningful improvement in event-free survival in resectable early-stage gastric and gastroesophageal junction cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2517482934","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517482934?lang=en_us&edition=fundamental","pubTime":"2025-03-07 20:00","pubTimestamp":1741348800,"startTime":"0","endTime":"0","summary":"MATTERHORN is first global, randomized Phase III trial to demonstrate superior event-free survival with an immunotherapy combination over standard of care in this setting. IMFINZI plus chemotherapy more than doubled pathologic complete response rate in previously reported analysis of this trial in 2023. WILMINGTON, Del., March 07, 2025----Positive high-level results from the MATTERHORN Phase III trial showed perioperative treatment with AstraZeneca’s IMFINZI  in combination with standard-of-care FLOT  chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival . Patients were treated with neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in combination with chemotherapy, then IMFINZI monotherapy. The trial evaluated this regimen versus perioperative chemotherapy alone for patients with resectable, early-stage and locally advanced  gastric and gastroesophageal j","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imfinzi-durvalumab-based-regimen-demonstrated-120000536.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4156","BK4124","AZN","BK4008","BK4532","CRT","BTC","LU1829250122.USD","BK4097","HSCT","LU2417539215.USD","BK4588","BK4007","BK4500","LU2462157665.USD","FLOT","HCC","OS","LU2456880835.USD","BK4568","BK4144","LU0109394709.USD","ALK","TEN","LU0320765992.SGD","VOD","BK4006","BK4213","BK4132","LU2236285917.USD","BK4582","BK4585","LU0889565916.HKD"],"gpt_icon":0},{"id":"2517438854","title":"Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2517438854","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517438854?lang=en_us&edition=fundamental","pubTime":"2025-03-07 19:59","pubTimestamp":1741348740,"startTime":"0","endTime":"0","summary":"Approval based on results of Phase 3 CheckMate -9DW clinical trial demonstrating a statistically significant and clinically meaningful improvement in overall survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib. PRINCETON, N.J., March 07, 2025----Bristol Myers Squibb  today announced that the European Commission  has approved Opdivo  plus Yervoy  for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma .\"The European Commission’s approval for Opdivo plus Yervoy adds to the growing body of evidence demonstrating the value of dual immunotherapy and represents an important new treatment option that may extend survival for patients with hepatocellular carcinoma,\" said Dana Walker, M.D., M.S.C.E., vice president, Opdivo global program lead, Bristol Myers Squibb. \"This approval marks a critical milestone in our commitment to improving outcomes for patients with liver cancer. We look forward to bringing this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-115900243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4132","ORR","AEIS","LU1868837300.USD","CRT","LU2242646821.SGD","LU0321505868.SGD","LU1032466523.USD","LU0096364046.USD","BK4581","LU1261432733.SGD","LU0225284248.USD","LU1430594728.SGD","MYE","BK4213","IE00B19Z4B17.USD","LU1291159041.SGD","LU2125154935.USD","VOD","LU0061475181.USD","LU1670711040.USD","CRC","LU0306807586.USD","ALK","LU1868836914.USD","LU1868837136.USD","IE00BFTCPJ56.SGD","LU0237698245.USD","BMY","IE00BSNM7G36.USD","EC","HSCT","HCC","OS","BK4532","LU0306806265.USD","BK4201","BK4097","TEN","BK4124","LU0321505439.SGD","RCC","LU1868836591.USD","LU0114720955.EUR","BK4157","LU0868494617.USD","IE00B7SZL793.SGD","LU1670710588.SGD","LU1571399168.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":127,"pageCount":10,"totalSize":2032}]}}